Role of ABCC5 in cancer drug resistance and its potential as a therapeutic target.

IF 4.6 2区生物学 Q2 CELL BIOLOGY

Frontiers in Cell and Developmental Biology Pub Date : 2024-11-05 eCollection Date: 2024-01-01 DOI:10.3389/fcell.2024.1446418

Yinlong Pan, Mengmeng Wu, Huazhong Cai

{"title":"Role of ABCC5 in cancer drug resistance and its potential as a therapeutic target.","authors":"Yinlong Pan, Mengmeng Wu, Huazhong Cai","doi":"10.3389/fcell.2024.1446418","DOIUrl":null,"url":null,"abstract":"<p><p>Over 90% of treatment failures in cancer therapy can be attributed to multidrug resistance (MDR), which can develop intracellularly or through various routes. Numerous pathways contribute to treatment resistance in cancer, but one of the most significant pathways is intracellular drug efflux and reduced drug concentrations within cells, which are controlled by overexpressed drug efflux pumps. As a member of the family of ABC transporter proteins, ABCC5 (ATP Binding Cassette Subfamily C Member 5) reduces the intracellular concentration of a drug and its subsequent effectiveness using an ATP-dependent method to pump the drug out of the cell. Numerous studies have demonstrated that ABCC5 is strongly linked to both poor prognosis and poor treatment response. In addition, elevated ABCC5 expression is noted in a wide variety of malignancies. Given that ABCC5 is regulated by several pathways in a broad range of cancer types, it is a prospective target for cancer treatment. This review examined the expression, structure, function, and role of ABCC5 in various cancer types.</p>","PeriodicalId":12448,"journal":{"name":"Frontiers in Cell and Developmental Biology","volume":"12 ","pages":"1446418"},"PeriodicalIF":4.6000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573773/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cell and Developmental Biology","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3389/fcell.2024.1446418","RegionNum":2,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CELL BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Over 90% of treatment failures in cancer therapy can be attributed to multidrug resistance (MDR), which can develop intracellularly or through various routes. Numerous pathways contribute to treatment resistance in cancer, but one of the most significant pathways is intracellular drug efflux and reduced drug concentrations within cells, which are controlled by overexpressed drug efflux pumps. As a member of the family of ABC transporter proteins, ABCC5 (ATP Binding Cassette Subfamily C Member 5) reduces the intracellular concentration of a drug and its subsequent effectiveness using an ATP-dependent method to pump the drug out of the cell. Numerous studies have demonstrated that ABCC5 is strongly linked to both poor prognosis and poor treatment response. In addition, elevated ABCC5 expression is noted in a wide variety of malignancies. Given that ABCC5 is regulated by several pathways in a broad range of cancer types, it is a prospective target for cancer treatment. This review examined the expression, structure, function, and role of ABCC5 in various cancer types.

查看原文本刊更多论文

ABCC5 在癌症耐药性中的作用及其作为治疗靶点的潜力。

90% 以上的癌症治疗失败可归因于多药耐药性 (MDR)，这种耐药性可在细胞内或通过各种途径产生。导致癌症耐药性的途径有很多，但最重要的途径之一是细胞内药物外流和细胞内药物浓度降低，这是由过度表达的药物外流泵控制的。作为 ABC 转运体蛋白家族的一员，ABCC5（ATP 结合盒 C 亚家族成员 5）通过一种依赖 ATP 的方法将药物泵出细胞，从而降低细胞内药物浓度，并降低药物疗效。大量研究表明，ABCC5 与预后不良和治疗反应差密切相关。此外，在多种恶性肿瘤中都发现 ABCC5 表达升高。鉴于 ABCC5 在多种癌症类型中受到多种途径的调控，因此它是癌症治疗的一个前瞻性靶点。本综述研究了 ABCC5 在各种癌症类型中的表达、结构、功能和作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Cell and Developmental Biology Biochemistry, Genetics and Molecular Biology-Cell Biology

CiteScore

9.70

自引率

3.60%

发文量

2531

审稿时长

12 weeks

期刊介绍： Frontiers in Cell and Developmental Biology is a broad-scope, interdisciplinary open-access journal, focusing on the fundamental processes of life, led by Prof Amanda Fisher and supported by a geographically diverse, high-quality editorial board. The journal welcomes submissions on a wide spectrum of cell and developmental biology, covering intracellular and extracellular dynamics, with sections focusing on signaling, adhesion, migration, cell death and survival and membrane trafficking. Additionally, the journal offers sections dedicated to the cutting edge of fundamental and translational research in molecular medicine and stem cell biology. With a collaborative, rigorous and transparent peer-review, the journal produces the highest scientific quality in both fundamental and applied research, and advanced article level metrics measure the real-time impact and influence of each publication.